Relay Therapeutics
RLAY
172 hedge funds and large institutions have $1.1B invested in Relay Therapeutics in 2023 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 67 increasing their positions, 47 reducing their positions, and 12 closing their positions.
92% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 12
84% more call options, than puts
Call options by funds: $195K | Put options by funds: $106K
43% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 47
7% more funds holding
Funds holding: 161 → 172 (+11)
0.23% less ownership
Funds ownership: 107.05% → 106.82% (-0.23%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
33% less capital invested
Capital invested by funds: $1.64B → $1.1B (-$541M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$14.8M |
| 2 |
CC
Casdin Capital
New York
|
+$9.95M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$7.68M |
| 4 |
O
OrbiMed
New York
|
+$5.4M |
| 5 |
Two Sigma Investments
New York
|
+$4.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$24.8M |
| 2 |
AG
Artal Group
Luxembourg
|
-$15.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.12M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$8.12M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$6.77M |
RLAY Hedge Fund Activity: Q3 2023 in Review
172 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q3 2023, worth a combined $1.1B — down 33% from $1.64B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new RLAY positions and 12 closed out — a net gain of 11 holders — while 67 added to existing stakes and 47 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $14.8M. The largest seller was State Street, cutting an estimated $24.8M.
- 172 institutional investors held Relay Therapeutics (RLAY) as of Q3 2023, up from 161 in Q2 2023.
- Funds reported $1.1B of Relay Therapeutics stock for Q3 2023, down 33% quarter-over-quarter.
- 23 funds opened new Relay Therapeutics positions in Q3 2023 and 12 closed out, a net change of +11 holders.
- The largest Relay Therapeutics buyer in Q3 2023 was Citadel Advisors, an estimated $14.8M added.
- The largest Relay Therapeutics seller in Q3 2023 was State Street, an estimated $24.8M sold.
Based on aggregated 13F filings for Q3 2023.